Kenvue Inc. Common Stock vs Merck & Co., Inc. — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 10.3× Kenvue Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| KVUE | MRK | |
|---|---|---|
Market Cap | $34.06B | $351.28B |
Volume | 23,267,228 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $19.83 | $156.43 |
52-Week Low | $14.11 | $82.49 |
Enterprise Value | $41.56B | $398.04B |
Dividend Yield | 4.74% | 2.39% |
Typical Hold Time | — | 98 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →